The hUC‐MSCs treatment significantly diminished supernatant concentrations of interferon‐γ, tumor necrosis factor‐α, interleukin (IL)‐4, and IL‐17 in SLE‐MS group, as well as inhibited HSP90AA1 in the glucose‐activated PI3K‐AKT pathway. Here, AKT1 is linked to myeloid sarcoma.